Log in
NASDAQ:AYLA

Ayala Pharmaceuticals Stock Forecast, Price & News

$9.67
-0.08 (-0.82 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.63
Now: $9.67▼
$9.90
50-Day Range
$9.75
MA: $11.54▼
$13.50
52-Week Range
$8.62
Now: $9.67▼
$16.50
Volume6,202 shs
Average Volume20,536 shs
Market Capitalization$123.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.

Beat the Market (BTM) Rank™

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.42 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AYLA
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.ayalapharma.com
Phone857-444-0553
Employees31

Debt

Debt-to-Equity RatioN/A
Current Ratio8.63
Quick Ratio8.63

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.33 million
Price / Sales53.04
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.67 per share
Price / Book2.63

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-17,790,000.00
Net Margins-850.81%
Return on Equity-625.24%
Return on Assets-70.31%

Miscellaneous

Outstanding Shares12,779,000
Market Cap$123.57 million
Next Earnings Date2/16/2021 (Estimated)
OptionableNot Optionable
$9.67
-0.08 (-0.82 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AYLA News and Ratings via Email

Sign-up to receive the latest news and ratings for AYLA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ayala Pharmaceuticals (NASDAQ:AYLA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Ayala Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ayala Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Ayala Pharmaceuticals?

Wall Street analysts have given Ayala Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ayala Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ayala Pharmaceuticals' next earnings date?

Ayala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for Ayala Pharmaceuticals.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) posted its earnings results on Tuesday, November, 17th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.04. Ayala Pharmaceuticals had a negative net margin of 850.81% and a negative return on equity of 625.24%.
View Ayala Pharmaceuticals' earnings history.

What price target have analysts set for AYLA?

4 analysts have issued 12 month target prices for Ayala Pharmaceuticals' shares. Their forecasts range from $23.00 to $25.00. On average, they anticipate Ayala Pharmaceuticals' share price to reach $24.00 in the next year. This suggests a possible upside of 148.2% from the stock's current price.
View analysts' price targets for Ayala Pharmaceuticals.

Who are some of Ayala Pharmaceuticals' key competitors?

Some companies that are related to Ayala Pharmaceuticals include CEL-SCI (CVM), Orchard Therapeutics (ORTX), CEL-SCI (CVM), Innate Pharma (IPHA), Innate Pharma (IPHYF), Freeline Therapeutics (FRLN), Cellular Biomedicine Group (CBMG), Cabaletta Bio (CABA), Harpoon Therapeutics (HARP), Prevail Therapeutics (PRVL), Surface Oncology (SURF), Codiak BioSciences (CDAK), Voyager Therapeutics (VYGR), CASI Pharmaceuticals (CASI) and Eiger BioPharmaceuticals (EIGR).
View all competitors.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Moderna (MRNA), CrowdStrike (CRWD), Dynavax Technologies (DVAX), Square (SQ), Abbott Laboratories (ABT), Alpine Immune Sciences (ALPN), Advanced Micro Devices (AMD), BioLineRx (BLRX), Cognex (CGNX) and Micron Technology (MU).

Who are Ayala Pharmaceuticals' key executives?

Ayala Pharmaceuticals' management team includes the following people:
  • Dr. Roni Mamluk, Pres, CEO & Director (Age 53, Pay $390.57k)
  • Mr. Yossi Maimon CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 49, Pay $424.88k)
  • Dr. Gary B. Gordon M.D., Ph.D., Chief Medical Officer (Age 67, Pay $323.26k)

When did Ayala Pharmaceuticals IPO?

(AYLA) raised $50 million in an initial public offering on Friday, May 8th 2020. The company issued 3,300,000 shares at $14.00-$16.50 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

What is Ayala Pharmaceuticals' stock symbol?

Ayala Pharmaceuticals trades on the NASDAQ under the ticker symbol "AYLA."

When did the company's lock-up period expire?

Ayala Pharmaceuticals' lock-up period expired on Wednesday, November 4th. Ayala Pharmaceuticals had issued 3,666,667 shares in its initial public offering on May 8th. The total size of the offering was $55,000,005 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.

Who are Ayala Pharmaceuticals' major shareholders?

Ayala Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (0.09%).

Which major investors are buying Ayala Pharmaceuticals stock?

AYLA stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC.

How do I buy shares of Ayala Pharmaceuticals?

Shares of AYLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ayala Pharmaceuticals' stock price today?

One share of AYLA stock can currently be purchased for approximately $9.67.

How big of a company is Ayala Pharmaceuticals?

Ayala Pharmaceuticals has a market capitalization of $123.57 million and generates $2.33 million in revenue each year. Ayala Pharmaceuticals employs 31 workers across the globe.

What is Ayala Pharmaceuticals' official website?

The official website for Ayala Pharmaceuticals is www.ayalapharma.com.

How can I contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals' mailing address is Oppenheimer 4, Rehovot L3, 7670104. The company can be reached via phone at 857-444-0553 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.